176 related articles for article (PubMed ID: 38216554)
1. Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
Galanis E; Dooley KE; Keith Anderson S; Kurokawa CB; Carrero XW; Uhm JH; Federspiel MJ; Leontovich AA; Aderca I; Viker KB; Hammack JE; Marks RS; Robinson SI; Johnson DR; Kaufmann TJ; Buckner JC; Lachance DH; Burns TC; Giannini C; Raghunathan A; Iankov ID; Parney IF
Nat Commun; 2024 Jan; 15(1):493. PubMed ID: 38216554
[TBL] [Abstract][Full Text] [Related]
2. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
Myers R; Harvey M; Kaufmann TJ; Greiner SM; Krempski JW; Raffel C; Shelton SE; Soeffker D; Zollman P; Federspiel MJ; Blanco M; Galanis E
Hum Gene Ther; 2008 Jul; 19(7):690-8. PubMed ID: 18576918
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
[TBL] [Abstract][Full Text] [Related]
4. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
[TBL] [Abstract][Full Text] [Related]
5. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
6. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
7. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
8. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
9. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
Allen C; Opyrchal M; Aderca I; Schroeder MA; Sarkaria JN; Domingo E; Federspiel MJ; Galanis E
Gene Ther; 2013 Apr; 20(4):444-9. PubMed ID: 22914495
[TBL] [Abstract][Full Text] [Related]
11. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).
Opyrchal M; Allen C; Iankov I; Aderca I; Schroeder M; Sarkaria J; Galanis E
Hum Gene Ther; 2012 Apr; 23(4):419-27. PubMed ID: 22185260
[TBL] [Abstract][Full Text] [Related]
12. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
Ammour Y; Susova O; Krasnov G; Nikolaeva E; Varachev V; Schetinina Y; Gavrilova M; Mitrofanov A; Poletaeva A; Bekyashev A; Faizuloev E; Zverev VV; Svitich OA; Nasedkina TV
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366531
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic measles virus strains in the treatment of gliomas.
Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein inhibitors increase the efficacy of measles virotherapy.
Liu C; Erlichman C; McDonald CJ; Ingle JN; Zollman P; Iankov I; Russell SJ; Galanis E
Gene Ther; 2008 Jul; 15(14):1024-34. PubMed ID: 18356818
[TBL] [Abstract][Full Text] [Related]
16. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
[TBL] [Abstract][Full Text] [Related]
17. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
19. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]